BioSpace News Archive

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease.

RAPT Therapeutics, Inc. today announced that members of the RAPT management team will participate in the following investor conferences in November.

Lyra Therapeutics, Inc. announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the following investor conferences in November.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10-2441425) entitled “Combined Preparations for the Treatment of Cancer” by the Japanese Patent Office and South Korean Patent Office, respectively.

Lipocine Inc. today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.

Medison Pharma announced the addition of South and Central America and the Caribbean markets to its multi-territorial agreement with Immunocore Holdings plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease.

YPrime, LLC., a global leader in cloud-based eClinical solutions, launched their electronic informed consent platform , which enables study teams to present increasingly complex study information to patients in highly navigable, digestible components that improve comprehension and boost engagement.

Baebies has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences.

Astria Therapeutics, Inc. announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming Jefferies London Healthcare Conference on Wednesday, November 16th at 7:25am GMT.